Chengdu Olymvax Biopharmaceuticals Inc.SSE: 688319

Announcement on Preliminary Earnings Estimate for 2024

Feb 28, 2025 · Issued by Chengdu Olymvax Biopharmaceuticals Inc. via Shanghai Stock Exchange

Filed with SSE · Feb 28, 2025

On 6ix: 6ix.com/news/announcement-on-preliminary-earnings-estimate-for-2024-124

Announcement on Preliminary Earnings Estimate for 2024

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Chengdu Olymvax Biopharmaceuticals Inc. on 6ix

Earlier from Chengdu Olymvax Biopharmaceuticals

Announcement on Voluntary Disclosure of Initiation of Phase I Clinical Trial for Trivalent and Tetravalent Influenza Vaccine (Split Virus, MDCK Cells) and Completion of First Subject EnrollmentFeb 22, 2025
Announcement on Obtaining Government SubsidyJan 23, 2025

Later from Chengdu Olymvax Biopharmaceuticals

Announcement on Change of Sponsor Institution and Sponsor RepresentativeMar 25, 2025
Announcement on Provision for Asset Impairment in 2024Mar 29, 2025
Announcement on Convening 2024 Annual Performance and Cash Dividend BriefingApr 1, 2025
Announcement on Resolutions of 2024 Annual General MeetingApr 19, 2025
Announcement on Attending the Annual Collective Performance Briefing for Innovative Drug Companies on SSE STAR Market 2024 and the Q1 2025 Performance BriefingApr 26, 2025

All Chengdu Olymvax Biopharmaceuticals news releases

Follow Chengdu Olymvax Biopharmaceuticals into a list and get an email when it puts out news.

Follow Chengdu Olymvax Biopharmaceuticals